CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 63.8 CNY -0.13% Market Closed
Market Cap: 7.3B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
CanSino Biologics Inc

Revenue
748.5m CNY
Cost of Revenue
-241.7m CNY
Gross Profit
506.8m CNY
Operating Expenses
-1.2B CNY
Operating Income
-667.8m CNY
Other Expenses
-52.4m CNY
Net Income
-720.1m CNY

Margins Comparison
CanSino Biologics Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
CanSino Biologics Inc
SSE:688185
7.3B CNY
68%
-89%
-96%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
749.7B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
372B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
257.3B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
201.7B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
163B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
179.6B CHF
75%
31%
35%
US
Pfizer Inc
NYSE:PFE
146B USD
71%
22%
7%
Country CN
Market Cap 7.3B CNY
Gross Margin
68%
Operating Margin
-89%
Net Margin
-96%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 372B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 201.7B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 163B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 179.6B CHF
Gross Margin
75%
Operating Margin
31%
Net Margin
35%
Country US
Market Cap 146B USD
Gross Margin
71%
Operating Margin
22%
Net Margin
7%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
CanSino Biologics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
CanSino Biologics Inc
SSE:688185
7.3B CNY
-13%
-8%
-10%
-14%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
749.7B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
372B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
257.3B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
201.7B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
163B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
179.6B CHF
45%
17%
24%
16%
US
Pfizer Inc
NYSE:PFE
146B USD
5%
2%
7%
8%
Country CN
Market Cap 7.3B CNY
ROE
-13%
ROA
-8%
ROCE
-10%
ROIC
-14%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 749.7B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 372B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 257.3B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 201.7B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 163B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 179.6B CHF
ROE
45%
ROA
17%
ROCE
24%
ROIC
16%
Country US
Market Cap 146B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top